GlassScriptPhysician profile
Mackenzie A Berry
NPI 1659049013
$2,935.59
in general payments reported to CMS, 2019-2025
29 companies · $1,002 in 2025
The $1,002 reported for 2025 was more than what 80% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $502 · 2022: $696 · 2023: $364 · 2024: $371 · 2025: $1,002.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,738.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,737.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $959.83 | 2022-2025 | |
| Amgen INC. | $191.68 | 2021-2022 | |
| Pfizer INC. | $187.28 | 2024-2025 | |
| Sk Life Science, INC. | $171.69 | 2021-2025 | |
| Kyowa Kirin, INC. | $134.17 | 2021-2022 | |
| Ucb, INC. | $127.69 | 2021-2025 | Zilbrysq, Briviact |
| Novartis Pharmaceuticals Corporation | $126.79 | 2023-2025 | |
| Livanova USA, INC. | $117.07 | 2022 | |
| Emd Serono, INC. | $101.97 | 2022-2024 | Mavenclad |
| Lilly USA, LLC | $93.16 | 2025 | Kisunla |
| Horizon Therapeutics Plc | $86.86 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $76.44 | 2021 | |
| Ge Healthcare | $73.91 | 2022-2025 | |
| Axsome Therapeutics, INC. | $72.95 | 2023-2024 | Sunosi |
| Alexion Pharmaceuticals, INC. | $54.57 | 2021-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $52.32 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $49.04 | 2022 | |
| Acadia Pharmaceuticals INC | $36.43 | 2023 | Nuplazid |
| Lundbeck LLC | $33.25 | 2025 | Rexulti |
| Genzyme Corporation | $31.90 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $26.06 | 2021 | |
| Avadel Cns Pharmaceuticals, LLC | $19.05 | 2025 | Lumryz |
| Eisai INC. | $18.64 | 2025 | |
| Impel Pharmaceuticals LLC | $18.50 | 2025 | Trudhesa |
| Avanir Pharmaceuticals, INC. | $16.35 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $15.86 | 2022 | |
| Greenwich Biosciences, INC. | $15.31 | 2021 | |
| Avion Pharmaceuticals | $13.82 | 2022 | |
| Genentech USA, INC. | $13.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mackenzie Berry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.